Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

7.125 +0.175 (+2.52%)
Streaming Delayed Price Updated: 1:23 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
VIR Stock Pops Amid Renewed Omicron Variant Concerns. Here’s Why.
Vir Biotechnology has a Covid-19 treatment that its CEO says will do well against new variants. Amid uncertainty, VIR stock is climbing. 
Via InvestorPlace
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Cumberland (NASDAQ:CPIX) shares rose 91.81% to $4.22 during Tuesday's pre-market session. The company's market cap stands at $62.4 million. First Wave... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about! 
Via InvestorPlace
Exposures Product Safety
50 Biggest Movers From Yesterday
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
Adagio shares soar on antibody potential against new COVID variant omicron
Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h... 
Via Benzinga
Exposures COVID-19
Why Vir Biotechnology Is Up More Than 13% Today
Investors are looking to capitalize on the latest curveball thrown by the coronavirus contagion. 
Via The Motley Fool
Exposures COVID-19
33 Stocks Moving In Monday's Mid-Day Session
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational... 
Via Benzinga
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
56 Biggest Movers From Friday
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 68.43% to $17.18 during Friday's pre-market session. The market value of their outstanding shares is at $119.6... 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded... 
Via Benzinga
US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B
The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The company's market cap stands at $66.5 million. The... 
Via Benzinga
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
3 Vaccine Stocks With Big Opportunities Outside of COVID-19
For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too. 
Via The Motley Fool
Exposures COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Why Vir Biotechnology Stock Is Sliding Today
Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
GlaxoSmithKline Drops Research On Otilimab In COVID-19
GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021
Upgrades According to Wedbush, the prior rating for Regions Financial Corp (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Monday
Wells Fargo boosted Bank of America Corporation (NYSE:B... 
Via Benzinga
GlaxoSmithKline: My Top Value Stock For The Week
GSK, one of the biggest pharmaceuticals companies in the world, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet for would-be investors, the stock is still very... 
Via Talk Markets
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach. 
Via Investor's Business Daily
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.